RT Journal Article
SR Electronic
T1 Equipment-free detection of SARS-CoV-2 and Variants of Concern using Cas13
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.01.21265764
DO 10.1101/2021.11.01.21265764
A1 Arizti-Sanz, Jon
A1 Bradley, A’Doriann
A1 Zhang, Yibin B.
A1 Boehm, Chloe K.
A1 Freije, Catherine A.
A1 Grunberg, Michelle E.
A1 Kosoko-Thoroddsen, Tinna-Solveig F.
A1 Welch, Nicole L.
A1 Pillai, Priya P.
A1 Mantena, Sreekar
A1 Kim, Gaeun
A1 Uwanibe, Jessica N.
A1 John, Oluwagboadurami G.
A1 Eromon, Philomena E.
A1 Kocher, Gregory
A1 Gross, Robin
A1 Lee, Justin S.
A1 Hensley, Lisa E.
A1 Happi, Christian T.
A1 Johnson, Jeremy
A1 Sabeti, Pardis C.
A1 Myhrvold, Cameron
YR 2021
UL http://medrxiv.org/content/early/2021/11/02/2021.11.01.21265764.abstract
AB The COVID-19 pandemic, and the recent rise and widespread transmission of SARS-CoV-2 Variants of Concern (VOCs), have demonstrated the need for ubiquitous nucleic acid testing outside of centralized clinical laboratories. Here, we develop SHINEv2, a Cas13-based nucleic acid diagnostic that combines quick and ambient temperature sample processing and lyophilized reagents to greatly simplify the test procedure and assay distribution. We benchmarked a SHINEv2 assay for SARS-CoV-2 detection against state-of-the-art antigen-capture tests using 96 patient samples, demonstrating 50-fold greater sensitivity and 100% specificity. We designed SHINEv2 assays for discriminating the Alpha, Beta, Gamma and Delta VOCs, which can be read out visually using lateral flow technology. We further demonstrate that our assays can be performed without any equipment in less than 90 minutes. SHINEv2 represents an important advance towards rapid nucleic acid tests that can be performed in any location.Competing Interest StatementC.A.F., P.C.S., and C.M. are co-inventors on patent PCT/US2018/022764, which covers the SHERLOCK and HUDSON technology for viral RNA detection held by the Broad Institute. J.A.-S., C.A.F., P.C.S., and C.M. are co-inventors on a US Provisional Patent Application directed to SHINE technology. P.C.S. is a co-founder of, shareholder in, and advisor to Sherlock Biosciences, Inc., as well as a Board member of and shareholder in Danaher Corporation. All other authors declare no competing interests.Funding StatementFunding was provided by DARPA D18AC00006. This work is made possible by support from Flu Lab and a cohort of generous donors through TEDs Audacious Project, including the ELMA Foundation, MacKenzie Scott, the Skoll Foundation, and Open Philanthropy. J.A.-S. is supported by a fellowship from la Caixa Foundation (ID 100010434, code LCF/BQ/AA18/11680098). C.M. is supported by start-up funds from Princeton University. For L.W., this work was funded under Agreement No. HSHQDC-15-C-00064 awarded to Battelle National Biodefense Institute (BNBI) by the Department of Homeland Security (DHS) Science and Technology (S&T) Directorate for the management and operation of the National Biodefense Analysis and Countermeasures Center (NBACC), a Federally Funded Research and Development Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received a non-human subjects research determination from the Broad Institute Office of Research Subject Protections (NHSR-4318). To conduct this research, de-identified nasopharyngeal swab patient samples were purchased from Boca Biolistics (USA). Additional de-identified clinical samples were obtained from studies evaluated and approved at the Center for Disease Control and Prevention (CDC). This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy (See e.g., 45 C.F.R. part 46; 21 definition of research as defined in and was conducted consistent with C.F.R. part 56; 42 U.S.C. 241(d), 46.102(l) but did not involve human applicable federal law and CDC U.S.C. 552a, 44 U.S.C. 3501 et seq.)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.